Generic Vyondys 53 Availability
Last updated on Apr 10, 2025.
Vyondys 53 is a brand name of golodirsen, approved by the FDA in the following formulation(s):
VYONDYS 53 (golodirsen - solution;intravenous)
-
Manufacturer: SAREPTA THERAPS INC
Approval date: December 12, 2019
Strength(s): 100MG/2ML (50MG/ML) [RLD]
Is there a generic version of Vyondys 53 available?
No. There is currently no therapeutically equivalent version of Vyondys 53 available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyondys 53. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent 10,227,590
Issued: March 12, 2019
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
Patent expiration dates:
- June 28, 2025✓✓
- June 28, 2025
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent 10,266,827
Issued: April 23, 2019
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
Patent expiration dates:
- June 28, 2025✓
- June 28, 2025
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent 10,421,966
Issued: September 24, 2019
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
Patent expiration dates:
- June 28, 2025✓✓
- June 28, 2025
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent 10,968,450
Issued: April 6, 2021
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
Patent expiration dates:
- June 28, 2025✓✓
- June 28, 2025
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent 10,995,337
Issued: May 4, 2021
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
Patent expiration dates:
- June 28, 2025✓✓
- June 28, 2025
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent 9,024,007
Issued: May 5, 2015
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
Patent expiration dates:
- June 28, 2025✓✓
- June 28, 2025
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent 9,994,851
Issued: June 12, 2018
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
Patent expiration dates:
- June 28, 2025✓✓
- June 28, 2025
-
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent RE47691
Issued: November 5, 2019
Inventor(s): Wilton Stephen Donald & Fletcher Sue & McClorey Graham
Assignee(s): The University of Western AustraliaAn antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
Patent expiration dates:
- June 28, 2028✓
- June 28, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 12, 2026 - INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
More about Vyondys 53 (golodirsen)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
